TOBRAMYCiN VERSUS GENTAMICIN FOR THE NEONATE.
, 1.8pg/ml tobramycin and 2.3+1g/ml gentamicin. There was no signlficant difference bet~een~tobramycin and gentamicin in the frequency of proteinuria, glucosuria, hematuria, casts or serum creatinine increase of over .4mg% during therapy. Definite nephro; toxicity occurred in 10% of each group. The tobramycin group showed lower average serum creatinjne by .3mg% and higher creat inine clearance by 7ml/min/1.73m both during and after therapy. After therapy, urine N-acetyl-P glucosaminidase was ,095.02 IU/mg creatinine for tobramycin and .24+.09 IU/mg creatinine for gentamicin. Ai though tobramycin use resulted In a smai i improvement in creatinine clearance and less enzymuria, the clinical significance of these observations appears minimal. (PMN) and examined the ability of relevant antibiotics to enter PMN and to kill intracellular Hib. PMN were exposed to relevant concentrations (30 pM) of "c-penicillin G (Pen) or l~-chloramphenicol (Cm). At intervals cells were separated from the incubation mixture by centrifugation over silicone oil. Intracellular and residual extracellular water content of PMN were determined by parallel incubation of cells in 3~ -Hz0 or 3 5~ -Na2S04. The cellular to extracellular ratio for Pen was 0.14 5 0.18 (n=5) and for Cm In a prospective double-blind randomized study, 20 newborn infants were given either NT or GT IV 5mg/kg/day, q 12h for presumed septicemia. After at least 4 doses of aminoglycoside antibiotic, serum samples were drawn prior to and 0.5, 2, 4, 8, and 12 hours after infusion. (Antibiotic concentrations in sera were determined by microbioassay). The following were determined for each drug: &=half life, kel=rate of elimination, Vp=apparent volume of central compartmert Cpo=theoretical concentrati n of aminoglycoside in plasma at t=O. Vidarabine has recently been shown to significantly reduce mortality and morbidity in infants with herpes simplex virus infection. However, pharmacokinetic data in infants have not been available. Concentrations of Vidarabine (ara-A) and its major metabolite, 9-f3-D-arabinofuranosylhypoxanthine (ara-HX) were serially measured in serum and urine on 10 occasions in 7 patients following a 12-hour infusion of ara-A. Doses ranged from 15-30 mg/~g. Blood samples were collected on ice into tubes containing 50 pg pentostatin. Ara-A and ara-HX were measured by HPLC. Ara-A was not detected in serum or urine at any time in any patient. Serum concentrations of ara-HX at the end of the 12-hour infusion ranged from 3.8 yg/ml to 11.4 pg/ml. Concentrations of ara-HX in urine were 5-10 fold serum concentrations. There was no consistent correlation between dose and serum concentration of ara-HX. Estimated half-lives varied from 3.4 hours to 8.6 hours (mean = 6.5 hours) except in one infant with severe hepatic disease in whom the t 112 was 16.2 hours. The mean t 112 was longer than that reported in adults (3-4 hours). However, no accumulation occurred with the doses employed. Ara-A appears to be rapidly deaminated in infants as in adults so that the parent compound is not detected in serum or urine. The relative bioavailability of intravenous (I.V.) chloramphenicol succinate (CAP-S) and oral chloramphenicol palmitate (CAP-P) was compared in 14 children ages 2 months to 8 years. Chloramphenicol and CAP-S were measured in serum and urine by HPLC. The area under the serum concentration vs time curve(AUC) of chloramphenicol and urinary excretion of CAP-S were determined in each child under steady-state conditions while receiving CAP-S and again while receiving CAP-P. In 12 of the 14 children AUC was greater during oral CAP-P therapy, in 1 patient AUC was unchanged, and in 1 patient AUC was slightly decreased during oral compared to I.V. therapy. The mean AUC was significantly greater during oral therapy compared to I.V. therapy (116.3e.8 mg.hrs/L vs 77.79.1 mg.hrs/L, pC.005).
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BIOAVAILABILITY OF ORAL CHLORAMPHENICOL PALMITATE
The relative bioavailability of I.V. CAP-S was 67% compared to oral CAP-P. This was explained by a loss of 39% of the I.V. dose in the urine as unhydrolyzed CAP-S. The dose of I.V. CAP-S did not correlate with AUC (r=.247). However, there was a significant correlation between dose of oral CAP-P and AUC (r=. 733, pC.005).
The bioavailability of oral CAP-P is superior to I.V. CAP-S. Furthermore, there is a greater correlation between dose and amount of active drug in the body when the oral preparation is used. Oral CAP-P appears to offer significant therapeutic advantages in patients who can tolerate oral medication.
